Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)

Launched by UNIVERSITY HOSPITAL FREIBURG · Nov 21, 2023

Keywords

ClinConnect Summary

This clinical trial, called CVID-pHT, is studying how to predict portal hypertension, a condition that affects the blood vessels in the liver, in patients who have Common Variable Immunodeficiency (CVID). The trial is taking place at the University Medical Center Freiburg in Germany and is looking for patients with CVID who are between the ages of 65 and 74. Participants will be asked to join during their routine annual visit, and they will undergo various tests, including blood tests and ultrasounds of the abdomen, to gather important health information.

If you decide to participate, you can expect to provide your medical history and undergo some evaluations, such as checking the stiffness of your liver and spleen. The study will also keep track of any significant signs of portal hypertension, like swollen veins in the esophagus or fluid buildup in the abdomen, over the next year. Participation is voluntary, and you must give written consent to join. However, if you have other chronic liver diseases, you won't be eligible for this trial. Your involvement may help researchers understand how to better predict and manage liver-related issues in patients with CVID.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with CVID
• Exclusion Criteria:
• • no written informed consent
• • concomitant chronic liver disease (viral hepatitis, alcoholic liver disease, steatitic liver disease, hemochromatosis, primary biliary cholangitis, primary sclerosis cholangitis, M. Wilson, alpha-1-antitrypsin deficiency)